Bayer’s Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

Shots:

• Vitrakvi has received approval under Health Canada’s NOC/c policy based on the clinical study evaluating Vitrakvi in adults and children with solid tumors harboring NTRK fusion
•  The clinical study resulted in 75% ORR with 22% CR, 90% ORR is observed in children and 69% in adults. Vitrakvi therapy should be initiated following confirmation of NTRK gene fusion in a tumor specimen using a validated test
• Vitrakvi is an oral selective TRK inhibitor act by shrinking the tumor or slowing/stopping its growth and has received FDA’s accelerated approval for solid tumors with NTRK gene fusion on Nov 26, 2018

Click here to­ read full press release/ article | Ref: Canada Newswire | Image: Financial Times